Hosted on MSN1mon
Arcturus stock holds $63 target amid Japan production nodThe firm's endorsement follows the announcement that Meiji Seika Pharma, a division of Meiji Holdings trading on the Tokyo Stock Exchange under ticker 2269, has been granted approval for a key ...
Meiji Seika Pharma Co. said on Dec. 25 it is seeking 10 million yen ($63,500) in damages from Kazuhiro Haraguchi, a Lower House member of the main opposition Constitutional Democratic Party of Japan.
The company is pleased to welcome Meiji Seika Pharma Co., Ltd, a leading Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy spanning over 75 ...
gave the green light to CSL and Arcturus’ COVID-19 vaccine ARCT-154 – also known as Lunar-COV19 – which will be commercialised in Japan by partner Meiji Seika Pharma. Japan is the first ...
We are very pleased to have recently received European Commission approval for KOSTAIVE® and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan.
We are very pleased to have recently received European Commission approval for KOSTAIVE® and MHLW approval for Meiji Seika Pharma and ARCALIS to add commercial manufacturing sites in Japan. Our team ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results